Opinions of Andalusian primary health care professionals about human papillomavirus and its vaccine
DOI:
https://doi.org/10.23938/ASSN.0126Keywords:
Primary health care. Human Papillomavirus. Vaccines. Qualitative research.Abstract
Background. The human papillomavirus (HPV) is the most common sexually transmitted disease, but its vaccination coverage is among the lowest in Andalusia. The aim of this study is to determine what primary health care professionals think and find out about the prevention of HPV infection among adolescents and the administration of the vaccine
Method. Qualitative study using 6 focus groups with professionals from Primary Health Care in Seville, Granada and Jaen. Fourty-five professionals participated. An analysis of the semantic content was made, and answers were categorized in thematic units.
Results. Professionals recognize the difficulties in reaching the adolescent population concerning prevention of sexual risk behaviors, due to lack of time and little concern amongst adolescents about the preventive measures. Although the professionals recognize the symptoms of Human Papillomavirus infection, some did not know about the disease in men as well as the association with other cancers other than cervical cancer. They hesitate over whether to recommend the vaccine or not, leaving the decision to vaccinate their daughters in the hands of the parents.
Conclusion. It would be advisable to establish strategies that improve the information that the professionals have about HPV as well as the benefits of the vaccine, so that they can transmit the benefits clearly and assertively to the parents. This would avoid parental uncertainty, improve vaccination rates, and decrease complications of infection (cancer).
Downloads
References
DE LA FUENTE VILLARREAL D, GUZMÁN LÓPEZ S, BARBOZA QUINTANA O, GONZÁ-LEZ RAMÍRE RA. Biología del virus del papiloma humano y técnicas de diagnóstico. Medicina Universitaria 2010; 12: 231-238.
BRUNI L, BARRIONUEVO-ROSAS L, ALBERO G, SERRANO B, MENA M, GÓMEZ D et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Spain. Summary Report 27 July 2017. http://www.hpvcentre.net/statistics/reports/ESP.pdf. Consultado el 14 de noviembre de 2017.
CLEVELAND JL, JUNGER ML, SARAIYA M, MARKOWITZ LE, DUNNE, EF, EPSTEIN JB. La conexión entre el virus del papiloma humano y los carcinomas orofaríngeos de cé-lulas escamosas en los Estados Unidos. J Am Dent Assoc 2011; 6: 248-258.
GRUPO DE TRABAJO VPH 2012. Revisión del Programa de Vacunación frente a Virus del Papiloma Humano en España. Ponencia de Programa y Registro de Vacunacio-nes. Ministerio de Sanidad, Servicios Sociales e Igualdad 2013. https://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/PapilomaVPH.pdf. Consultado el 14 de noviembre de 2017.
BOSCH FX, MORENO D, REDONDO E, TORNÉ A. Vacuna nonavalente frente al virus del papiloma humano. Actualización 2017. SEMERGEN - Medicina de Familia 2017; 43: 265-276.
OLIVER SE, UNGER ER, LEWIS R, MCDANIEL D, GARGANO JW, STEINAU M et al. Prevalence of human papillomavirus among females after vaccine introduction-National Health and Nutrition Examination Survey, United States 2003-2014. J In-fect Dis 2017; 216: 594-603.
MINISTERIO DE SANIDAD, SERVICIOS SOCIALES E IGUALDAD. Coberturas de Vacu-nación. Datos estadísticos. Madrid 2016.
https://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/CoberturasVacunacion/Tabla8.pdf. Consultado el 1 de agosto de 2017.
PÉREZ MRO, VIOLETA VB, DEL CAMPO AV, RUIZ C, CASTAÑO SY, CONDE LPP et al. Cross-sectional study about primary health care professionals views on the inclu-sion of the vaccine against human papillomavirus in the vaccine schedules. Infec-tious Agents and Cancer 2015; 10: 41. doi: 10.1186/s13027-015-0034-9.
ROSENTHAL SL, WEISS TW, ZIMET GD, MA L, GOOD MB, VICHNIN MD. Predictors of HPV vaccine uptake among women aged 19-26: Importance of a physician’s recommendation. Vaccine 2011; 29: 890-895.
CONSEJERÍA DE SALUD Y BIENESTAR SOCIAL. Programas de prevención de la salud en los centros educativos de Andalucía. Valoración de profesionales de atención primaria. Curso 2010/2011. Junta de Andalucía 2012. http://www.juntadeandalucia.es/salud/export/sites/csalud/galerias/documentos/p_4_p_2_promocion_de_la_salud/programas_del_entorno_escolar/programas_promocion_salud/p_salud_centros_educativos_2011_12.pdf. Consultado el 3 de julio de 2017.
LIMA-SERRANO M, LIMA-RODRIGUEZ JS. Efecto de la estrategia de promoción de salud escolar Forma Joven. Gac Sanit 2017. http://dx.doi.org/10.1016/j.gaceta.2016.12.009
ARANCÓN CARNICERO C. Enfermera escolar «dextra» enfermera comunitaria. Rev Enferm 2010; 33: 28-29.
NUNES BP, FLORES TR, DURO SM, SAES MO, TOMASI E, SANTIAGO AD et al. Utilização dos serviços de saúde por adolescentes estudo transversal de base populacional, Pelotas-RS, 2012. Epidemiol Serv Saude 2015; 4: 411-420.
PALAZZO L, BERIA JU, TOMASI E. Adolescentes que utilizan servicios de atención primaria: ¿cómo viven? ¿por qué buscan ayuda y cómo se expresan? Cad Saúde Pú-blica 2003; 19: 1655-1665.
COLOMER-REVUELTA J. Prevención del embarazo en la adolescencia. Rev Pediatr Aten Primaria 2013; 15: 261-269.
SAURA SANJAUME S, FERNANDEZ DE SANMAMED SANTOS, MJ, VICENS VIDAL L, PUIGVERT VIU N, MASCORT NOGUÉ C, GARCÍA MARTÍNEZ J. Percepción del riesgo de contraer una enfermedad de transmisión sexual en población joven. Aten Primaria 2010; 42: 143-148.
DRAGO F, CICCARESE G, ZANGRILLO F, GASPARINI G, COGORNO L, RIVA S et al. A survey of current knowledge on sexually transmitted diseases and sexual behaviour in Italian adolescents. Int J Environ Res Public Health 2016; 13: 422. doi: 10.3390/ijerph13040422.
WHITE L, WALDROP J, WALDROP C. Human papillomavirus and vaccination of males: knowledge and attitudes of registered nurses. Pediatr Nurs 2016; 42: 21-30.
VALENTINO K, PORONSKY CB. Human papillomavirus infection and vaccination. J Pediatr Nurs 2016; 31: e155-e166.
NADARZYNSKI T, SMITH HE, RICHARDSON D, FORD E, LLEWELLYN CD. Sexual healthcare professionals' views on HPV vaccination for men in the UK. Br J Cancer 2015 1; 113: 1599-1601.
BRIANTI P, DE FLAMMINEIS E, MERCURI SR. Review of HPV-related diseases and cancers. New Microbiol 2017; 40: 80-85.
SOON R, DELA CRUZ MR, TSARK JU, CHEN JJ, BRAUN KL. A survey of physicians' attitudes and practices about the human papillomavirus (HPV) vaccine in Hawai’i. Hawaii J Med Public Health 2015; 74: 234-241.
BROTHERTON JM, JIT M, GRAVITT PE, BRISSON M, KREIMER AR, PAI SI et al. Eu-rogin roadmap 2015: how has HPV knowledge changed our practice: vaccines. Int J Cancer 2016; 139: 510-517.
SOCIEDADES CIENTÍFICAS ESPAÑOLAS. Documento de consenso vacunación frente al virus del papiloma humano. Consenso de sociedades científicas 2011. http://vacunasaep.org/sites/vacunasaep.org/files/VPH_Consenso_Sociedades_2011.pdf. Consultado el 10 de julio de 2017.
MILLS J, VAN WINKLE P, SHEN M, HONG C, HUDSON S. Physicians’, nurses’, and medical assistants’ perceptions of the human papillomavirus vaccine in a large inte-grated health care system. Perm J 2016; 20. doi: 10.7812/TPP/15-205.
PÉREZ MR, VIOLETA VB, DEL CAMPO AV, RUIZ C, CASTAÑO SY, CONDE LP et al. Cross-sectional study about primary health care professionals views on the inclusion of the vaccine against human papillomavirus in the vaccine schedules. Infect Agent Cancer 2015 16; 10-41.
KAVANAGH K, POLLOCK KG, CUSCHIERI K, PALMER T, CAMERON RL, WATT C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017; 17: 1293-1302.
WORLD HEALTH ORGANIZATION. Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec 2017; 92: 241-268. http://apps.who.int/iris/bitstream/10665/255353/1/WER9219.pdf?ua=1. Consultado el 18 de noviembre de 2017.
SCOTT K, BATTY ML. HPV vaccine uptake among Canadian youth and the role of the nurse practitioner. J community health 2016; 41: 197-205.
BETSCHA C, BREWERB NT, BROCARDC P, DAVIESD P, GAISSMAIERE W, ASEA N et al. Opportunities and challenges of Web 2.0 for vaccination decisions. Vaccine 2012; 30: 3727-3733.
FU LY, ZOOK K, SPOEHR-LABUTTA Z, HU P, JOSEPH JG. Search engine ranking, quality, and content of web pages that are critical versus noncritical of human papil-lomavirus vaccine. J Adolesc Health 2016; 58: 33-39.
SOTIRIADIS A, DAGKLIS T, SIAMANTA V, CHATZIGEORGIOU K, AGORASTOS T. LY-SISTRATA Study Group. Increasing fear of adverse effects drops intention to vac-cinate after the introduction of prophylactic HPV vaccine. Arch Gynecol Obstet 2012; 285: 1719-1724.
STILLO M, CARRILLO SANTISTEVE P, LOPALCO PL. Safety of human papillomavirus vaccines: a review. Expert Opin Drug Saf 2015; 14: 697-712.
GACVS Safety update on HPV vaccines. Geneva 2013. http://www.who.int/vaccine_safety/committee/topics/hpv/130619HPV_VaccineGACVSstatement.pdf. Consultado el 2 de junio de 2017.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
